11 hrs ago
HDFC Healthcare Fund Reports 30.19% CAGR Amid Sector Growth
HDFC Pharma and Healthcare Fund invests in companies connected to medicine and healthcare.
It has earned an average annual return of 30.19% since it began.
Its one-year return was 19.01% as of July 31, 2026.
The fund owns businesses such as drug makers, hospitals and medical equipment companies.
HDFC Mutual Fund believes India’s healthcare industry may grow over time.
More people may need healthcare because of ageing, lifestyle diseases and rising incomes.
However, this fund focuses on one sector, so it can be riskier than a fund spread across many industries.
Investors should consider their goals and risk tolerance because earlier returns may not continue.
HDFC Pharma and Healthcare Fund delivered a 30.19% CAGR since its launch on October 4, 2023.
The fund recorded a one-year return of 19.01% and a net asset value of Rs 21.069 as of July 31, 2026.
It invests mainly in pharmaceutical and healthcare companies, including hospitals, biotechnology, medical equipment and healthcare services.
HDFC Mutual Fund cited rising healthcare spending, exports, insurance coverage and India’s pharmaceutical manufacturing position as growth drivers.
The fund house cautioned that sectoral funds carry higher risks than diversified equity funds and that past returns do not guarantee future performance.
- Who
- HDFC Mutual Fund and fund manager Nikhil Mathur; HDFC AMC Managing Director and CEO Navneet Munot also commented on the strategy.
- What
- HDFC Pharma and Healthcare Fund reported a 30.19% CAGR since launch and a 19.01% one-year return.
- Where
- The fund focuses on India’s pharmaceutical and healthcare sector.
- When
- The fund launched on October 4, 2023; performance figures were reported as of July 31, 2026.
- Why
- HDFC Mutual Fund expects long-term demand to be supported by healthcare spending, exports, ageing, lifestyle diseases, rising incomes and greater insurance penetration.
Growth opportunity
Investment risk
Healthcare-sector prospects
Growth opportunity
HDFC Mutual Fund said India’s healthcare industry has structural growth potential because of rising domestic demand, higher healthcare spending, export opportunities and the country’s pharmaceutical manufacturing position.
Investment risk
The fund is concentrated in one sector, which the article says makes it riskier than diversified equity mutual funds.
Future returns
Growth opportunity
The fund house identified opportunities in complex generics, biosimilars, speciality drugs, contract development and manufacturing, hospitals, diagnostics and medical technology.
Investment risk
Investors were cautioned that past performance may not continue and does not guarantee future returns.
Key facts
- Fund
- HDFC Pharma and Healthcare Fund
- Launch date
- October 4, 2023
- Since-launch CAGR
- 30.19%
- One-year return
- 19.01% as of July 31, 2026
- Net asset value
- Rs 21.069 as of July 31, 2026
- Fund manager
- Nikhil Mathur
- Investment focus
- Pharmaceuticals, hospitals, healthcare services, biotechnology, medical equipment and supplies
- Risk consideration
- Sectoral funds may carry higher risks than diversified equity mutual funds
Sources
Related news
Invesco India Pharma and Healthcare Fund opens NFO
SBI Healthcare Fund Delivers 20% Plus SIP Returns
HSBC Consumption Fund Completes Three Years, Delivers 15.13% CAGR
Brokerages See Up to 55% Upside in Seven Stocks
After Two Flat Years, Nifty Outlook Turns More Balanced
Why a ₹10,000 SIP May Overstate Long-Term Wealth
Glass Wall Systems IPO Draws Broad Subscribe Calls
Fund Manager Tenure Matters Beyond Historical Mutual Fund Returns
